Several other studies have identified genes that could be targeted to promote tumor immunotherapy; for example, the loss of Ptpn2 and Adar1 was found to improve antigen presentation and tumor sensitisation to anti‐PD‐1 blockade to improve immunotherapy, respectively.44, 125. This evidence concerns the gene PTPN2 and neoplasm.